A Study to Evaluate the Single Dose Safety, Tolerability and Pharmacokinetics of IV BCX4430

Marburg Virus Disease Clinical Trial

Official title:
A Phase 1 Double-blind, Placebo Controlled, Dose Ranging Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Galidesivir (BCX4430) Administered as Single Doses Via Intravenous Infusion in Healthy Subjects

Status Completed

Clinical Trial Summary

This is a placebo-controlled, randomized, double-blind study to evaluate the pharmacokinetics of galidesivir following administration of single doses by IV infusion

Clinical Trial Description

This single ascending dose study will evaluate the safety, tolerability, and PK of single doses of galidesivir vs. placebo administered as IV infusions in healthy subjects enrolled in up to four dose cohorts of 8 subjects each. A single dose of study drug will be administered per cohort: 6 subjects will receive galidesivir IV, and 2 subjects will receive matching placebo. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03800173
Study type	Interventional
Source	BioCryst Pharmaceuticals
Contact
Status	Completed
Phase	Phase 1
Start date	December 10, 2018
Completion date	April 30, 2019

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03475056` - cAd3-Marburg Vaccine in Healthy Adults	Phase 1
Active, not recruiting	`NCT05817422` - Monovalent Chimpanzee Adenoviral-Vectored Marburg Virus Vaccine in Healthy Adults	Phase 2
Completed	`NCT04723602` - Evaluation of Safety, Tolerability and Immune Responses of Ebola-S and Marburg Vaccines in Healthy Adults	Phase 1
Completed	`NCT00605514` - Ebola and Marburg Virus Vaccines	Phase 1
Recruiting	`NCT06265012` - Study to Evaluate the Recombinant Vesicular Stomatitis Virus (rVSV)-Marburg Virus Vaccine Candidate (PHV01) in Healthy Adult Subjects	Phase 1
Completed	`NCT00997607` - Evaluating an Ebola and a Marburg Vaccine in Uganda	Phase 1